Clinical Trials Arena reports that Pilatus Biosciences has begun dosing in Hong Kong within its ongoing Phase I study of PLT012. The investigational treatment is being evaluated for HCC.
Trial conduct and operationsAI summary
Read at Clinical Trials Arena